Voltar
Artigo Revisado por pares
BIBTEX RIS

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study

2014; Springer Nature; Volume: 17; Issue: 4 Linguagem: Inglês

10.1038/pcan.2014.24

ISSN

1476-5608

Autores

Laurence Klotz, Darrell Drachenberg, Rajat Singal, Armen Aprikian, Yves Fradet, Marlene Kebabdjian, Marc Zarenda, Joseph L. Chin,

Tópico(s)

Sexual Differentiation and Disorders

Referência(s)